Bazex-Dupre-Christol Syndrome – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Bazex-Dupre-Christol (BDC) syndrome is characterized clinically by multiple basal cell carcinomas of the face that primarily occur in the second and third decade of life, follicular atrophoderma primarily of the dorsum sides of the hands and feet, and generalized hypotrichosis; occasionally with pili torti and trichorrhexis nodosa. Milia, hypohidrosis, and calcifying epithelial tumors are all symptoms of BDC. Four members of one family with BDC syndrome, a mother and her three daughters, were reported in this study. The major clinical features of BDC were very typical in the mother and one of the daughters, whereas the other two daughters only had follicular atrophoderma, milia, and hypotrichosis. Bazex Dupre Christol Syndrome is a hereditary multiple basal cell carcinoma (BCC) syndrome whose inheritance pattern is X-linked dominant, implying that all daughters of affected mothers should have this disease.
Bazex-Dupre-Christol (BDC) incidence
ranges from 1 to 1.5 cases per million population.
The competitive
landscape of Bazex-Dupre-Christol Syndrome includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Bazex-Dupre-Christol
Syndrome across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Bazex-Dupre-Christol
Syndrome Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Comments
Post a Comment